Viewray (NASDAQ:VRAY) posted its quarterly earnings results on Monday. The company reported ($0.38) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.25) by ($0.13), Briefing.com reports. The firm had revenue of $19.90 million for the quarter, compared to the consensus estimate of $21.23 million. The business’s quarterly revenue was up 23.6% compared to the same quarter last year.
Shares of Viewray (NASDAQ:VRAY) opened at $7.81 on Wednesday. The company has a debt-to-equity ratio of -1.67, a quick ratio of 1.20 and a current ratio of 1.59. Viewray has a twelve month low of $4.40 and a twelve month high of $10.64.
Several hedge funds have recently added to or reduced their stakes in VRAY. Park West Asset Management LLC acquired a new stake in shares of Viewray in the 4th quarter worth about $24,217,000. Sectoral Asset Management Inc acquired a new stake in shares of Viewray in the 4th quarter worth about $8,772,000. Citadel Advisors LLC increased its holdings in shares of Viewray by 2,115.4% in the 4th quarter. Citadel Advisors LLC now owns 669,054 shares of the company’s stock worth $6,195,000 after acquiring an additional 638,854 shares during the period. EAM Investors LLC acquired a new stake in shares of Viewray in the 4th quarter worth about $4,463,000. Finally, Vanguard Group Inc. increased its holdings in shares of Viewray by 67.0% in the 2nd quarter. Vanguard Group Inc. now owns 1,026,880 shares of the company’s stock worth $6,644,000 after acquiring an additional 411,866 shares during the period. 63.22% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: “Viewray (VRAY) Releases Earnings Results, Misses Estimates By $0.13 EPS” was first posted by BBNS and is owned by of BBNS. If you are accessing this news story on another site, it was illegally copied and republished in violation of U.S. & international copyright & trademark legislation. The correct version of this news story can be read at https://baseballnewssource.com/2018/03/14/viewray-vray-releases-earnings-results-misses-estimates-by-0-13-eps/2028070.html.
Viewray Company Profile
ViewRay, Inc designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered.
Receive News & Ratings for Viewray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viewray and related companies with MarketBeat.com's FREE daily email newsletter.